The effectiveness of eptifibatide in the prevention of thrombotic complications in the endovascular treatment of acute myocardial infarction against a background of coronavirus infection

Objective: to study the effectiveness of eptifibatide in the prevention of thrombotic complications in the endovascular treatment of acute myocardial infarction against the background of coronavirus infection. Materials and methods: a retrospective analysis of the results of emergency intervention was performed in 60 patients with acute occlusion of the infarct-dependent artery against the background of concomitant new coronary infection COVID-19. The patients were divided into 2 statistically homogeneous groups of 30 people each. In the first (main) group, the drug «Eptifibatide» was administered to patients before performing percutaneous coronary intervention, in the second (control) group, the drug was not used. The efficiency of restoring coronary blood flow was determined according to the evaluation method by the number of coronary angiography frames for which the revascularized artery was filled with contrast agent: up to 20 frames - complete restoration of coronary blood flow, from 20 to 40 - partial, over 40 frames - unrecoverable. The number of thrombotic complications and adverse events (fatal outcome, repeated myocardial infarction, repeated emergency intervention) was recorded after the intervention. Results: In the first group, complete restoration of coronary blood flow was achieved in 60%, partial - in 30%, blood flow was not restored - 10%, and in the second group, respectively, in 30%, 50% and 20% of patients. In the first group, thrombotic complications developed in 6.7%, and in the second group in 26.7%, adverse events occurred respectively in 10% and 23.3% of patients. Conclusion: the use of the drug "Eptifibatide” in endovascular treatment of myocardial infarction against the background of coronavirus infection accelerates coronary blood flow, reduces the number of thrombotic complications and adverse events.